Establishment and internal validation of a model to predict the efficacy of Adalimumab in Crohn’s disease
Abstract Background: Clinically, the ability to distinguish which Crohn’s disease patients can benefit from Adalimumab is limited. Aims: This study aimed to develop a model for predicting clinical remission probability for Crohn’s disease patients with Adalimumab at 12 weeks. The model assists clini...
Saved in:
Main Authors: | Fang Wang, He Zhou, Yujie Zhang, Yu Da, Tiantian Zhang, Yanting Shi, Tong Wu, Jie Liang |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-024-82855-0 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Innovative Assessment of Crohn’s Disease: An Activity Prediction Tool Combining Laboratory Data and Imaging [Letter]
by: Wang F, et al.
Published: (2025-02-01) -
Systemic Immune-Inflammation Index: A Promising, Non-Invasive Biomarker for Crohn’s Disease Activity and Severity Assessment
by: Deng Y, et al.
Published: (2025-01-01) -
Adalimumab for endoscopic and histopathological mucosal healing in paediatric patients with moderate to severe Crohn’s disease
by: Edyta Szymanska, et al.
Published: (2016-12-01) -
A Nomogram Based on Laboratory Data, Inflammatory Bowel Disease Questionnaire and CT Enterography for Activity Evaluation in Crohn’s Disease
by: Zhang H, et al.
Published: (2025-01-01) -
Adalimumab induced psoriasis in Crohn’s disease and treatment with ustekinumab: case report and special histopathological findings
by: Fang Qiu, et al.
Published: (2025-01-01)